We are excited to announce that Vectura Fertin Pharma, Inc. has formally transitioned to a new corporate identity, Aspeya, Inc.
The new identity reflects the organization’s broad focus on developing and commercializing consumer health and wellness products, and its quest to provide new treatments for specific therapy areas.
Michael Kunst, CEO, Aspeya, said: “We are thrilled to embrace our new identity. Aspeya is a name that represents our high aspirations, the different aspects we take in the multiple areas where we operate, and our hope and ambition to make a positive difference to people’s lives. We continue our journey to empower healthier lifestyles and target specific unmet needs in our pursuit of ‘responsibility by design’.”
The introduction of a new corporate identity follows the divestment of Vectura Group Limited on December 31, 2024.
About Aspeya
We are on a journey to empower healthier lifestyles and target specific unmet needs. We do this by being innovative, optimizing formulas, and applying rigorous scientific standards across four areas of focus: Consumer health, cannabinoids, inhaled therapeutics, and nicotine replacement therapy. We’re harnessing deep insight and scientific expertise to reimagine how ingredients can be used, and working towards the development and commercialization of a pipeline of wellness and healthcare products and brands. Aspeya was formed in March 2022 and operates as a separate company under the ownership of Philip Morris International.
Contact
Richard Oakley
Director Communications, Aspeya